Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Alpa Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹178.82Undervalued by 189.82%vs CMP ₹61.70

P/E (29.7) × ROE (7.9%) × BV (₹93.40) × DY (2.00%)

₹93.72Undervalued by 51.90%vs CMP ₹61.70
MoS: +34.2% (Strong)Confidence: 43/100 (Low)Models: 4 Under, 3 Fair, 2 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹172.4823%Under (+179.5%)
Graham NumberEarnings₹108.5816%Under (+76%)
Earnings PowerEarnings₹65.6311%Fair (+6.4%)
DCFCash Flow₹57.0114%Fair (-7.6%)
Net Asset ValueAssets₹93.507%Under (+51.5%)
EV/EBITDAEnterprise₹25.639%Over (-58.5%)
Earnings YieldEarnings₹56.107%Fair (-9.1%)
ROCE CapitalReturns₹79.267%Under (+28.5%)
Revenue MultipleRevenue₹52.215%Over (-15.4%)
Consensus (9 models)₹93.72100%Undervalued
Key Drivers: Wide model spread (₹26–₹172) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -3.5%

*Investments are subject to market risks

Analyst Summary

Alpa Laboratories Ltd operates in the Pharmaceuticals segment, NSE: ALPA | BSE: 532878, current market price is ₹61.70, market cap is 130 Cr.. At a glance, stock P/E is 29.7, ROE is 7.90 %, ROCE is 8.91 %, book value is 93.4, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹93.72, which is about 51.9% above the current price, so the page currently reads as potentially undervalued rather than fully priced. On operating trend, latest reported sales are about ₹110 Cr versus the prior period change of 0.9%, while latest net profit is about ₹20 Cr with a prior-period change of 17.6%. The 52-week range shown on this page is 100/46.0, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAlpa Laboratories Ltd. is a Public Limited Listed company incorporated on 18/03/1988 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN)…

This summary is generated from the stock page data available for Alpa Laboratories Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

51
Alpa Laboratories Ltd scores 51/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health66/100 · Strong
ROCE 8.9% AverageROE 7.9% AverageD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 57.2% Stable
Earnings Quality50/100 · Moderate
OPM stable around 7% Steady
Quarterly Momentum40/100 · Moderate
Revenue (4Q): +13% YoY GrowingProfit (4Q): -10% YoY DecliningOPM: -11.2% (down 24.3% YoY) Margin pressure
Industry Rank35/100 · Weak
P/E 29.7 vs industry 54.6 Cheaper than peersROCE 8.9% vs industry 25.3% Below peersROE 7.9% vs industry 18.4% Below peers3Y sales CAGR: -1% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 5:05 am

Market Cap 130 Cr.
Current Price 61.7
Intrinsic Value₹93.72
High / Low 100/46.0
Stock P/E29.7
Book Value 93.4
Dividend Yield0.00 %
ROCE8.91 %
ROE7.90 %
Face Value 10.0
PEG Ratio-8.37

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Alpa Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Alpa Laboratories Ltd 130 Cr. 61.7 100/46.029.7 93.40.00 %8.91 %7.90 % 10.0
Lactose (India) Ltd 125 Cr. 99.0 137/76.018.0 51.50.00 %11.3 %9.81 % 10.0
Par Drugs & Chemicals Ltd 125 Cr. 101 122/78.08.61 91.00.00 %16.5 %12.4 % 10.0
Bal Pharma Ltd 136 Cr. 85.2 99.0/59.718.8 51.61.41 %9.69 %7.87 % 10.0
Krebs Biochemicals & Industries Ltd 115 Cr. 53.2 82.5/38.3 75.50.00 %15.4 %% 10.0
Industry Average23,072.45 Cr1,307.3954.56215.820.36%25.34%18.37%6.02

All Competitor Stocks of Alpa Laboratories Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 13.5427.3129.1625.4332.3927.3123.6121.4424.9426.1539.1119.1125.63
Expenses 19.2824.6819.9026.5829.0724.8520.1020.9021.6725.4139.4718.6928.50
Operating Profit -5.742.639.26-1.153.322.463.510.543.270.74-0.360.42-2.87
OPM % -42.39%9.63%31.76%-4.52%10.25%9.01%14.87%2.52%13.11%2.83%-0.92%2.20%-11.20%
Other Income 6.382.69-0.764.472.953.553.975.186.918.803.2411.963.69
Interest 0.080.070.040.020.040.030.300.050.060.100.050.050.05
Depreciation 0.360.100.530.280.490.660.520.540.530.550.580.550.67
Profit before tax 0.205.157.933.025.745.326.665.139.598.892.2511.780.10
Tax % -0.00%-0.00%41.74%-0.00%-0.00%14.85%46.70%-0.00%20.44%-0.00%186.67%-0.00%-0.00%
Net Profit 0.205.144.623.035.744.533.555.127.638.89-1.9511.780.10
EPS in Rs 0.102.442.201.442.732.151.692.433.634.23-0.935.600.05

Last Updated: February 6, 2026, 6:47 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 6:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 565753636277859711293109110114
Expenses 515447565776799010185100105114
Operating Profit 6377416811895-1
OPM % 10%6%13%11%7%2%7%8%10%9%8%5%-1%
Other Income 12645504119142319
Interest 2212110000000
Depreciation 9611111121222
Profit before tax -5-3119755112016212616
Tax % 4%-48%27%34%27%36%20%33%28%21%19%24%
Net Profit -5-18653471413172012
EPS in Rs -2.45-0.673.682.852.271.401.943.456.726.007.989.355.61
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)80.00%900.00%-25.00%-16.67%-40.00%33.33%75.00%100.00%-7.14%30.77%17.65%
Change in YoY Net Profit Growth (%)0.00%820.00%-925.00%8.33%-23.33%73.33%41.67%25.00%-107.14%37.91%-13.12%

Alpa Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:6%
3 Years:0%
TTM:4%
Compounded Profit Growth
10 Years:55%
5 Years:30%
3 Years:36%
TTM:39%
Stock Price CAGR
10 Years:19%
5 Years:27%
3 Years:15%
1 Year:-8%
Return on Equity
10 Years:7%
5 Years:9%
3 Years:11%
Last Year:11%

Last Updated: September 4, 2025, 11:00 pm

Balance Sheet

Last Updated: June 16, 2026, 5:00 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 212121212121212121212121
Reserves 66737782858996111124141161176
Borrowings 292411620063502
Other Liabilities 132720172121332830255153
Total Liabilities 128145129127129131150165178192233251
Fixed Assets 555666797112120
CWIP 000001200000
Investments 102223415968628690109129153
Other Assets 113118100796456807081728378
Total Assets 128145129127129131150165178192233251

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + -2-25-8-7-118-121041810
Cash from Investing Activity + 37-71-16-15-116-161-13-12-12
Cash from Financing Activity + 7-6-24-5-1-05-32-51
Net Cash Flow 42-37-9-19-2054-88-70-0
Free Cash Flow -3-25-10-9-215-409-376
CFO/OP -92%-320%-71%-133%116%316%18%54%171%85%445%388%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow6.00-26.00-17.00-4.00-2.00-1.006.008.005.005.004.005.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 130156234169151141105133124186138155
Inventory Days 148761961311401059010281847392
Days Payable 121912441401309998152781006397
Cash Conversion Cycle 1571411871601611489783127170149150
Working Capital Days 65-4224197204189121137124150132108
ROCE %-3%0%10%11%7%4%7%7%9%11%14%15%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters 57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.29%57.19%57.19%
FIIs 0.11%0.95%0.50%0.36%0.74%0.35%0.40%0.36%0.35%0.36%0.38%0.35%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.07%
Public 42.59%41.74%42.21%42.35%41.97%42.34%42.30%42.34%42.36%42.35%42.43%42.38%
No. of Shareholders 18,56518,68218,69018,11618,88519,20618,87218,85118,54218,23617,90017,643

Shareholding Pattern Chart

No. of Shareholders

Alpa Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 9.348.015.886.703.44
Diluted EPS (Rs.) 9.348.015.886.703.44
Cash EPS (Rs.) 10.328.906.617.484.03
Book Value[Excl.RevalReserv]/Share (Rs.) 81.4872.2063.9657.8551.16
Book Value[Incl.RevalReserv]/Share (Rs.) 81.4872.2063.9657.8551.16
Revenue From Operations / Share (Rs.) 53.4551.6844.1853.3646.36
PBDIT / Share (Rs.) 13.3610.938.2910.195.75
PBIT / Share (Rs.) 12.3110.007.669.405.16
PBT / Share (Rs.) 12.209.837.559.305.13
Net Profit / Share (Rs.) 9.277.975.986.703.44
NP After MI And SOA / Share (Rs.) 9.277.975.986.703.44
PBDIT Margin (%) 24.9821.1418.7619.0912.39
PBIT Margin (%) 23.0319.3517.3317.6111.13
PBT Margin (%) 22.8219.0117.0917.4211.05
Net Profit Margin (%) 17.3415.4213.5312.557.42
NP After MI And SOA Margin (%) 17.3415.4213.5312.557.42
Return on Networth / Equity (%) 11.3711.049.3411.576.73
Return on Capital Employeed (%) 14.7213.6311.9015.9710.07
Return On Assets (%) 8.769.197.529.075.16
Long Term Debt / Equity (X) 0.000.000.010.010.00
Total Debt / Equity (X) 0.000.030.010.040.00
Asset Turnover Ratio (%) 0.550.620.570.730.71
Current Ratio (X) 4.125.744.674.433.73
Quick Ratio (X) 3.745.254.283.933.22
Inventory Turnover Ratio (X) 7.188.273.733.963.73
Interest Coverage Ratio (X) 121.2364.0278.0197.84155.24
Interest Coverage Ratio (Post Tax) (X) 85.1447.7157.2765.3294.03
Enterprise Value (Cr.) 216.89179.04106.65149.5765.56
EV / Net Operating Revenue (X) 1.931.651.151.330.67
EV / EBITDA (X) 7.727.796.116.985.42
MarketCap / Net Operating Revenue (X) 1.951.611.221.300.77
Price / BV (X) 1.281.160.841.200.70
Price / Net Operating Revenue (X) 1.951.611.221.300.77
EarningsYield 0.080.090.110.090.09

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Alpa Laboratories Ltd and is it undervalued?

As of 06 September 2026, Alpa Laboratories Ltd's intrinsic value is ₹93.72, which is 51.90% higher than the current market price of ₹61.70, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (7.90 %), book value (₹93.4), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Alpa Laboratories Ltd?

Alpa Laboratories Ltd is trading at ₹61.70 as of 06 September 2026, with a FY2026-2027 high of ₹100 and low of ₹46.0. The stock is currently in the middle of its 52-week range. Market cap stands at ₹130 Cr..

How does Alpa Laboratories Ltd's P/E ratio compare to its industry?

Alpa Laboratories Ltd has a P/E ratio of 29.7, which is below the industry average of 54.56. This is broadly in line with or below the industry average.

Is Alpa Laboratories Ltd financially healthy?

Key indicators for Alpa Laboratories Ltd: ROCE of 8.91 % is on the lower side compared to the industry average of 25.34%; ROE of 7.90 % is below ideal levels (industry average: 18.37%). Dividend yield is 0.00 %.

Is Alpa Laboratories Ltd profitable and how is the profit trend?

Alpa Laboratories Ltd reported a net profit of ₹20 Cr in Mar 2025 on revenue of ₹110 Cr. Compared to ₹14 Cr in Mar 2022, the net profit shows an improving trend.

Does Alpa Laboratories Ltd pay dividends?

Alpa Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹61.70. The company is currently not paying meaningful dividends.

Last Updated: August 25, 2026, 5:05 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532878 | NSE: ALPA
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Alpa Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports